Personalised organoid models may improve immunotherapy treatment
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
Researchers at the Wake Forest Organoid Research Center (WFORCE), US, have been using patient-specific tumour organoid models as a pre-clinical companion platform to better evaluate immunotherapy for appendiceal cancer, one of the rarest forms of cancer.
Appendiceal cancer is resistant to systemic chemotherapy, however WFORCE created the organoids to use as a predictive model for potential treatment options. The organoids are part of the Wake Forest Institute of Regenerative Medicine (WFIRM)’s “body-on-a-chip” system that allows scientists to engineer the organoids, or human tissue equivalents, that function in a very similar manner as actual human organs.
In the new study, the team’s results indicated that various types of immunotherapies tested on the organoids can potentially support treatment decisions and can achieve personalised results, identifying beneficial therapies while sparing patients from any harmful side effects.
Cells from tumour biopsies from 16 patients were obtained to grow the organoids which were then treated with one of three immunotherapy drugs and assessed for responsiveness. “For this study we reconstructed patients’ tumours as organoids, supercharged with a built-in immune system directly obtained from the patient,” explained senior author Konstantinos Votanopoulos. “In this way we created a personalised interface to study how effective the immunotherapy drugs are in activating a patient’s own immune system to kill the cancer.”
Co-author Shay Soker added that new technologies and biological models that improve prognostication will have a significant effect on patient mortality. “Using the organoids as a pre-clinical platform can lead to development of novel therapeutics which target and control tumour cells specifically, sparing healthy tissue from the side effects of chemotherapy and immunotherapy treatments,” he said. “For rare cancers like appendiceal cancer, this technology can make a difference in overall quality of life for patients.”
The new study was published in Clinical Cancer Research.